We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Local Infiltration Analgesia During Total Knee Arthroplasty (LIA)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2012 by Mika Niemeläinen, Coxa, Hospital for Joint Replacement.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01305733
First Posted: March 1, 2011
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Mika Niemeläinen, Coxa, Hospital for Joint Replacement
  Purpose
The primary objective is to evaluate whether local infiltration analgesia (LIA) will reduce oxycodone consumption during the first 48 postoperative hours in patients undergoing total knee arthroplasty (TKA).

Condition Intervention
Pain Drug: The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline Other: saline injection

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Local Infiltration Analgesia During Total Knee Arthroplasty - Reduced Opiate Consumption and Faster Mobilisation Postoperatively - Randomized Controlled Trial

Resource links provided by NLM:


Further study details as provided by Mika Niemeläinen, Coxa, Hospital for Joint Replacement:

Primary Outcome Measures:
  • oxycodone consumption during the first 48 postoperative hours [ Time Frame: 48 hours ]

Secondary Outcome Measures:
  • functional outcome after TKA [ Time Frame: 1 year ]

Enrollment: 60
Study Start Date: March 2011
Estimated Study Completion Date: December 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: local infiltration analgesia
The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
Drug: The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
Placebo Comparator: saline injection
The normal saline injection are used in the control group in the same manner than in the RKA group.
Other: saline injection
saline

Detailed Description:
The goal of LIA is to gain an effective and safe pain control during the first postoperative days. The study is a single-center, randomized controlled trial, which will be performed in Coxa Hospital for Joint Replacement in Tampere, Finland. The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline with occasional variations if the patient is unusually small, very elderly, infirm or has a history of significant intolerance to analgesics or anesthetic agents. The RKA mixture is diluted with normal saline. Total volume of the solution is 100 ml depending on the size of the wound. The normal saline injection are used in the control group in the same manner than in the RKA group.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients requiring primary TKA for primary OA
  • Patients aged 75 years or less
  • Patients suitable for all applicable devices

Exclusion Criteria:

  • Rheumatoid arthritis or other inflammatory diseases
  • Patients requiring bone grafting during surgery
  • Unwilling to provide informed consent
  • BMI > 35
  • ASA > 3
  • Renal dysfunction
  • Allergic to ASA
  • Previous high tibial osteotomy or previous osteosynthesis
  • > 15 degrees varus / valgus malalignment
  • Physical, emotional or neurological conditions which would comprise the patient´s compliance with postoperative rehabilitation and follow-up (e.g. drug or alcohol abuse, serious mental illness, general neurological conditions such as Parkinson, MS, etc.)
  • Known sensitivity to materials in the devices
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01305733


Locations
Finland
Coxa - hospital for joint replacement
Tampere, Pirkanmaa, Finland, 33560
COXA
Tampere, Pirkanmaa, Finland, 33560
Sponsors and Collaborators
Coxa, Hospital for Joint Replacement
Investigators
Study Director: Antti Eskelinen, M.D., Ph.D Coxa, Hospital for Joint Replacement
Principal Investigator: Mika Niemeläinen, MD Coxa, Hospital for Joint Replacement
  More Information

Responsible Party: Mika Niemeläinen, orthopaedic surgeon, Coxa, Hospital for Joint Replacement
ClinicalTrials.gov Identifier: NCT01305733     History of Changes
Other Study ID Numbers: Coxa - LIA
First Submitted: February 28, 2011
First Posted: March 1, 2011
Last Update Posted: October 12, 2017
Last Verified: May 2012

Keywords provided by Mika Niemeläinen, Coxa, Hospital for Joint Replacement:
Pain relief

Additional relevant MeSH terms:
Ketorolac
Ketorolac Tromethamine
Levobupivacaine
Bupivacaine
Epinephrine
Racepinephrine
Epinephryl borate
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Anti-Asthmatic Agents
Respiratory System Agents